heterologous booster
Showing 1 - 25 of 1,093
COVID-19 Trial in Bandung (SARS-CoV-2 subunit protein recombinant vaccine)
Not yet recruiting
- COVID-19
- SARS-CoV-2 subunit protein recombinant vaccine
-
Bandung, Jawa Barat, IndonesiaFaculty of Medicine Universitas Padjadjaran
Feb 13, 2023
COVID-19 Trial in Chengdu (LYB002V14, LYB002V14A, LYB002CA)
Active, not recruiting
- COVID-19
- LYB002V14
- +2 more
-
Chengdu, Sichuan, ChinaAffiliated Hospital of North Sichuan MedicalCollege
Jun 29, 2023
COVID-19, Vaccine Reaction Trial in Chengdu (LYB001, CoronaVac)
Active, not recruiting
- COVID-19
- Vaccine Reaction
- LYB001
- CoronaVac
-
Chengdu, Sichuan, ChinaChengdu Xinhua Hospital Affiliated to North Sichuan Medical Coll
Jun 29, 2023
SARS-CoV-2 Trial in Islamabad (LVRNA009, CoronaVac®)
Not yet recruiting
- SARS-CoV-2
- LVRNA009
- CoronaVac®
-
Islamabad, PakistanClinical Trial Unit, National Institute of Health
Jun 22, 2022
COVID-19 Trial (GBP510 adjuvanted with AS03, Placebo (Normal Saline))
Not yet recruiting
- COVID-19
- GBP510 adjuvanted with AS03
- Placebo (Normal Saline)
- (no location specified)
Aug 11, 2022
COVID-19 Trial in Cali (VLA 2001)
Not yet recruiting
- COVID-19
- VLA 2001
-
Cali, Valle, ColombiaCentro de Estudios en Infectología Pediátrica
Sep 15, 2022
Immunogenicity, Safety, Efficacy Trial in Savannakhét (SW-BIC-213;SARS-Cov-2., Sinopharm (BIBP);SARS-Cov-2.,
Active, not recruiting
- Immunogenicity
- +2 more
- SW-BIC-213;SARS-Cov-2.
- +2 more
-
Savannakhét, Sava, Lao People's Democratic RepublicSavannakhét Provincial hospital
Jan 8, 2023
SARS-CoV-2, Safety, Immunotoxicity Trial in Wuhan (one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006), Cellular Immunity,
Not yet recruiting
- SARS-CoV-2
- +2 more
- one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
- +3 more
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Aug 9, 2022
Immunogenicity, Safety Trial (Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;)
Not yet recruiting
- Immunogenicity
- Safety
- Phase II:SWIM816;SARS-Cov-2;
- +3 more
- (no location specified)
Jun 18, 2023
SARS-CoV-2 Infection Trial in Bangkok (Full dose of Ad26.COV2. 5x10^10vp, Half dose of Ad26.COV2. 2.5x10^10vp)
Recruiting
- SARS-CoV-2 Infection
- Full dose of Ad26.COV2. 5x10^10vp
- Half dose of Ad26.COV2. 2.5x10^10vp
-
Bangkok, ThailandVaccine Trial Centre, Faculty of Tropical Medicine, Mahidol Univ
Sep 11, 2022
Multiple Sclerosis Trial in Derby (Homologous booster, Heterologous booster)
Recruiting
- Multiple Sclerosis
- Homologous booster
- Heterologous booster
-
Derby, ConnecticutGriffin Hospital
Jan 23, 2022
COVID-19 Pandemic Trial (Lyophilized COVID-19 mRNA Vaccine, Sodium chloride)
Not yet recruiting
- COVID-19 Pandemic
- Lyophilized COVID-19 mRNA Vaccine
- Sodium chloride
- (no location specified)
Nov 18, 2022
COVID-19 Trial in Adelaide (SpikoGen vaccine)
Not yet recruiting
- COVID-19
- SpikoGen vaccine
-
Adelaide, South Australia, AustraliaARASMI
Sep 13, 2022
COVID-19 Vaccine Trial in Kaohsiung, Taipei (Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222)
Recruiting
- COVID-19 Vaccine
- Half dose of MVC-COV1901
- +3 more
-
Kaohsiung, Taiwan
- +3 more
Mar 28, 2022
Covid19 Trial in Hamburg (MVA-SARS-2-S vaccinations (days 0 & 28), Comirnaty)
Completed
- Covid19
- MVA-SARS-2-S vaccinations (days 0 & 28)
- Comirnaty
-
Hamburg, GermanyCTC North GmbH & Co KG at the University Medical Center Hamburg-
Nov 4, 2021
Pertussis Immunisation, Diphtheria Immunisation, Tetanus Immunisation Trial in Cape Town (Tetanus Toxoid, Reduced Diphtheria
Recruiting
- Pertussis Immunisation
- +3 more
- Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine
-
Cape Town, South Africa
- +2 more
Dec 2, 2022
COVID-19 Trial in Singapore (Homologous mRNA booster vaccine, Heterologous mRNA booster vaccine, Non-mRNA booster vaccine A)
Recruiting
- COVID-19
- Homologous mRNA booster vaccine
- +4 more
-
Singapore, SingaporeNational Centre for Infectious Diseases (NCID)
Nov 30, 2021
COVID-19 (Healthy Volunteers) Trial in Korea, Republic of (SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of
Not yet recruiting
- COVID-19 (Healthy Volunteers)
- SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03
- Normal saline
-
Ansan, Korea, Republic of
- +9 more
Jan 3, 2022
Influenza, Human, Infections, Respiratory Tract Infections Trial in United States (aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on
Not yet recruiting
- Influenza, Human
- +4 more
- aH5N8c on Day 1
- +4 more
-
Cullman, Alabama
- +8 more
May 15, 2023
Kidney Transplant Recipient Trial in Phoenix, Jacksonville, Rochester (Janssen Ad26.CoV2.S Vaccine, Reduction in
Recruiting
- Kidney Transplant Recipient
- Janssen Ad26.CoV2.S Vaccine
- +2 more
-
Phoenix, Arizona
- +2 more
Jul 14, 2022
Influenza, Human, Influenza in Birds, Respiratory Tract Infections Trial in United States (aH5N6c on Day 1, aH5N6c on Day 22,
Recruiting
- Influenza, Human
- +7 more
- aH5N6c on Day 1
- +2 more
-
Huntsville, Alabama
- +17 more
Jul 26, 2022
Ebola Virus Disease Trial in Goma, Kinshasa (Zabdeno® booster, Ervebo® booster)
Not yet recruiting
- Ebola Virus Disease
- Zabdeno® booster
- Ervebo® booster
-
Goma, Congo, The Democratic Republic of the
- +1 more
Nov 6, 2023
COVID-19 Trial in United States (NVX-CoV2373 (5µg), NVX-CoV2601 (5µg), NVX-CoV2601(5µg))
Not yet recruiting
- COVID-19
- NVX-CoV2373 (5μg)
- +6 more
-
Birmingham, Alabama
- +47 more
Jul 2, 2023
COVID-19, Vaccine Reaction, COVID-19 Pandemic Trial in San Francisco (Moderna Booster Vaccine, Pfizer Booster Vaccine)
Enrolling by invitation
- COVID-19
- +2 more
- Moderna Booster Vaccine
- Pfizer Booster Vaccine
-
San Francisco, CaliforniaUCSF Parnassus
Mar 1, 2022
COVID-19, Breakthrough Infection Trial in Taoyuan city (BNT162b2, mRNA-1273, MVC-COV1901)
Active, not recruiting
- COVID-19
- Breakthrough Infection
- BNT162b2
- +2 more
-
Taoyuan city, TaiwanChang Gung Memorial Hospital
Jul 21, 2022